AlloVir Inc (ALVR)

24.72 +0.02  +0.08% NASDAQ Oct 22, 16:00 24.75 +0.03  +0.12% After-Hours: 20:00 USD
View Full Chart
Price Chart
View All ALVR News

News

View All Events

Events

Date Type Description
11/10/2021 Earnings Results Q3 2021 Earnings Results
08/06/2021 Earnings Results Q2 2021 Earnings Results
05/25/2021 10:15 EST AGM 2021 Annual General Meeting
05/06/2021 Earnings Results Q1 2021 Earnings Results
02/11/2021 Earnings Results Q4 2020 Earnings Results
11/10/2020 Earnings Results Q3 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • Description: AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
  • URL: https://www.allovir.com
  • Investor Relations URL: https://ir.allovir.com/
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: N/A
  • Next Earnings Release: Nov. 10, 2021
  • Last Earnings Release: Aug. 06, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.